The development of a synthetic process for ( S, S )-reboxetine succinate, a candidate for the treatment of fibromylagia, is disclosed from initial scale-up to deliver material for registrational stability testing through to commercial route evaluation and subsequent nomination. This entailed evaluation of several alternative routes to result in what would have been a commercially attractive process for launch of the compound.
No takes yet. Share an insight, caveat, or question.
Hayes et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: